<DOC>
	<DOC>NCT01270555</DOC>
	<brief_summary>The investigators propose to conduct an open study to evaluate the efficacy and tolerability of Bupropion SR using clinically relevant doses in ADHD adults with a recent history of or current substance use disorders. We hypothesize that Bupropion SR will be effective in treating ADHD in this population.</brief_summary>
	<brief_title>Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Male and female outpatients 18 years old or older, up to 60 years old. Patients with the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSMIV, as manifested in clinical evaluation and confirmed by structured interview. Patients within the past 6 months known to abuse or to be dependent on alcohol or any drug (nicotine addiction not included) Any clinically unstable medical condition Clinically significant abnormal baseline laboratory values Mental retardation (I.Q. &lt;75) or Organic brain disorders Seizure disorder Patients with a history or an eating disorder including anorexia or bulimia nervosa Pregnant or nursing females Patients with current bipolar disorder Psychotic disorder of any type Patients on psychotropics known to treat ADHD (i.e. stimulants, tricyclics) Patients receiving psychotherapy known to treat ADHD (i.e. cognitive or cognitive/behavioral psychotherapy) Patients demonstrating active withdrawal from substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>